Metabolic Syndrome
Conditions
Brief summary
HDL in obese non-diabetic patients show major alterations in their function and thus their cardio-protective effects. These alterations could be explained by the quantitative and qualitative anomalies in the phospholipids and sphingolipids in the HDL. These molecules play a major role in HDL function and probably present early modifications in obesity, even before the onset of glycaemia deregulation. The aim of this study is to show the presence of qualitative and quantitative modifications of phospholipids and sphingolipids in HDL from obese patients compared with HDL from non-obese controls.
Interventions
BIOLOGICALBlood sample
Sponsors
Centre Hospitalier Universitaire Dijon
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* aged \> 18 years * fasting glycaemia \< 1.10 g/l * waist circumference \> 102 cm for men and 88 cm for women (criteria NCEP/ATP III) * 2 criteria among the following 3 (NCEP/ATP III criteria for metabolic syndrome): * triglyceridaemia ≥ 1.50 g/l * HDL cholesterol \< 0.40 g/l for men and 0.50 g/l for women * arterial blood pressure ≥ 130/85 mmHg or treatment for arterial hypertension * patients who have provided written consent INCLUSION CRITERIA FOR HEALTHY SUBJECTS * age \> 18 years * fasting glycaemia \< 1.10 g/l * waist circumference \< 102 cm for men and 88 cm for women * triglyceridaemia \< 1.50 g/l * HDL cholesterol ≥ 0.40 g/l for men and 0.50 g/l for women * Healthy subjects who have provided written consent
Exclusion criteria
* Persons without national health insurance cover * Diabetes * Diseases that interfere with lipoprotein metabolism (dysthyroidism not controlled with the treatment, kidney or liver disease) * Treatments that interfere with lipoprotein metabolism (lipid-lowering agents, oestrogens, corticoids, retinoids, antiretroviral agents) * Pregnancy/breast feeding
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Difference in the mass percentages of total phospholipids + sphingolipids compared with the total HDL mass | At inclusion | in patients with abdominal obesity without hyperglycaemia compared with healthy controls |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Difference in the percentage of each family of phospholipids or sphingolipids compared with total phospholipids + sphingolipids | At inclusion | in patients with abdominal obesity but without hyperglycaemia compared with healthy controls |
| Difference in the percentage of each sub-family according to the nature of the fatty acids for phosphatidylcholines on the one hand and sphingomyelins on the other in patients | At inclusion | with abdominal obesity but without hyperglycaemia compared with healthy control |
Countries
France
Outcome results
None listed